George Bakris
University of Chicago
H-index: 161
North America-United States
Top articles of George Bakris
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression | Diabetes, Obesity and Metabolism | Frederick Berro Rivera Grace Nooriza O Lumbang Danielle Rose Magno Gaid Linnaeus Louisse A Cruz John Vincent Magalong | 2024/3/20 |
Meta-Analyses of Blood Pressure Lowering Trials | George L Bakris Costas Thomopoulos | 2024/1/1 | |
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With … | Circulation | Brendon L Neuen Hiddo JL Heerspink Priya Vart Brian L Claggett Robert A Fletcher | 2024/2/6 |
MORTALITY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH HEART FAILURE AND CHRONIC KIDNEY DISEASE WITH RECURRENT HYPERKALEMIA: REVOLUTIONIZE III STUDY | Atherosclerosis | J Brinck E Hagström J Nåtman S Franzén B Eliasson | 2021/8/1 |
Real-World Impact of Blood Pressure Control in Patients With Apparent Treatment-Resistant or Difficult-to-Control Hypertension and Stages 3 and 4 Chronic Kidney Disease | American Journal of Hypertension | George Bakris Cindy Chen Alicia K Campbell Veronica Ashton Lloyd Haskell | 2024/3/4 |
Hypertension and Chronic Kidney Disease Including Dialysis | Omar Al Dhaybi George L Bakris | 2024/1/1 | |
Albuminuria is Your Guide to Assessing Future GFR Slope | Kidney International Reports | Omar Al Dhaybi George L Bakris | 2024/2/1 |
Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials | BMJ open | Shweta Bansal Maria EF Canziani Rita Birne Stefan D Anker George L Bakris | 2024/3/1 |
Overview of the Evolution of Hypertension: From Ancient Chinese Emperors to Today | George L Bakris Michael A Weber | 2024/4 | |
Initial Combination Therapies | Hala Yamout George L Bakris | 2024/1/1 | |
Did the SCORED Trial Get Extra Points for Kidney Outcomes? If So, It Is Not Obvious | Nupur Mistry George L Bakris | 2024/1/24 | |
Diabetic Kidney Disease Prevention Care Model Development | Clinical Diabetes | Nuha A ElSayed Raveendhara R Bannuru George Bakris Joan Bardsley Ian H de Boer | 2024/4/1 |
Rilparencel (Renal Autologous Cell Therapy-REACT®) for Chronic Kidney Disease and Type 1 and 2 Diabetes: Phase 2 Trial Design Evaluating Bilateral Kidney Dosing and Re-Dosing … | American Journal of Nephrology | Joseph Stavas Arnold L Silva Thomas D Wooldridge Ahmed Aqeel Theodore Saad | 2024/2/29 |
Resistant hypertension: cardiorenal protection with mineralocorticoid receptor blockade | Bertram Pitt George L Bakris | 2024/1/7 | |
Approach to difficult to manage primary hypertension | Matthew J Sorrentino George L Bakris | 2024/1/1 | |
Prediction of cardiovascular and renal risk among patients with apparent treatment‐resistant hypertension in the United States using machine learning methods | The Journal of Clinical Hypertension | George Bakris Pei Lin Chang Xu Cindy Chen Veronica Ashton | 2024/3/24 |
Update: Newer alternatives for resistant hypertension: Beyond 2022 paradigms | George L Bakris | 2024 | |
Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis | Diabetes, Obesity and Metabolism | Nikolaos Perakakis Stefan R Bornstein Andreas L Birkenfeld Andreas Linkermann Münevver Demir | 2024/1 |
RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial | JAMA | George L Bakris Manish Saxena Anil Gupta Fadi Chalhoub Jongtae Lee | 2024/2/16 |
Effects Of Aprocitentan, A Dual Endothelin Receptor Antagonist, On Blood Pressure In Black/African American Patients With Resistant Hypertension: Results From A Randomized … | Hypertension | John M Flack Markus Schlaich Michael Weber George Bakris Wentao Lu | 2023/9 |
Co-Authors
